Navigation Links
Royalty Pharma Announces that Alexander von Perfall Joins Management Team

NEW YORK, Dec. 7 /PRNewswire/ -- Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.


Alexander has 13 years of cross-border management advisory, strategic planning and principal investment experience, most recently as co-founder and Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings Agency. He previously advised the International Finance Corporation/World Bank Group on the syndication of media sector private equity investments. Alexander started his career with Bertelsmann AG where he held various management positions, culminating with a position as Director of Business Development where he initiated and oversaw investments in a number of early stage media and entertainment ventures. Alexander attended the Hoschchule St. Gallen in Switzerland before obtaining a BA in Politics from the University of San Francisco and an MBA from the New York University - Stern School of Business.

"The addition of Alexander to our management team adds an important element of investor relationship management," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Alexander will play a key role in Royalty Pharma's efforts to enhance its investor and key stakeholder strategy and communication, including acting as a liaison between Royalty Pharma's management team and equity and debt investors, the analyst community and media representatives."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property - principally royalty interests in marketed and late stage biopharmaceutical products with approximately $6 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including Abbott's Humira®, J&J/Merck's Remicade®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Gilead's Emtriva®, Truvada® and Atripla®, and Celgene's Thalomid®. Royalty Pharma has a thirteen year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica® royalty from Northwestern University, its $650 million purchase of the Remicade® royalty from New York University, its $700 million purchase of the Humira® royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen® and Neulasta® for over $400 million. For more information, go to

For additional information, please contact:
Pablo Legorreta                                Alexander v. Perfall
Chief Executive Officer                        VP, Investor Relations
+ 1 (212) 883-2288                             + 1 (212) 883-2298         

More information on Royalty Pharma is available at

SOURCE Royalty Pharma

SOURCE Royalty Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting
8. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
9. Amber Pharmacy Earns Accreditation From ACHC
10. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
11. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... announced that it has undertaken significant expansion of its current state of the ... is part of PharmaTech’s strategy to increase its manufacturing capacity as well as ...
Breaking Medicine News(10 mins):